Sol-Gel Technologies (SLGL) Stock Price, News & Analysis

Company Overview

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Key Stats

• Today's Range: $0.53 to $0.59
• 50-Day Range: $0.53 to $1.05
• 52-Week Range: $0.33 to $1.65
• Volume: 16,238 shs
• Average Volume: 252,696 shs
• Market Capitalization: $14.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Sol-Gel Technologies Stock Analysis - MarketRank™

Sol-Gel Technologies scored higher than 49% of companies evaluated by MarketBeat, and ranked 604th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Sol-Gel Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Sol-Gel Technologies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Sol-Gel Technologies are expected to decrease in the coming year, from ($0.28) to ($0.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sol-Gel Technologies is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sol-Gel Technologies is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sol-Gel Technologies has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.12% of the float of Sol-Gel Technologies has been sold short.

Short Interest Ratio / Days to Cover

Sol-Gel Technologies has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sol-Gel Technologies has recently increased by 79.17%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sol-Gel Technologies does not currently pay a dividend.

Dividend Growth

Sol-Gel Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.12% of the float of Sol-Gel Technologies has been sold short.

Short Interest Ratio / Days to Cover

Sol-Gel Technologies has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sol-Gel Technologies has recently increased by 79.17%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.43

News Sentiment

Sol-Gel Technologies has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Sol-Gel Technologies this week, compared to 0 articles on an average week.

MarketBeat Follows

Only 1 people have added Sol-Gel Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sol-Gel Technologies insiders have not sold or bought any company stock.

Percentage Held by Insiders

66.51% of the stock of Sol-Gel Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 26.18% of the stock of Sol-Gel Technologies is held by institutions.

SLGL Stock Analysis - Frequently Asked Questions

How have SLGL shares performed this year?

Sol-Gel Technologies' stock was trading at $0.9301 at the start of the year. Since then, SLGL stock has decreased by 43.1% and is now trading at $0.5290.
View the best growth stocks for 2025 here.

How were Sol-Gel Technologies' earnings last quarter?

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) released its earnings results on Friday, August, 16th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.27. The business had revenue of $5.43 million for the quarter, compared to the consensus estimate of $1.06 million. Sol-Gel Technologies had a negative trailing twelve-month return on equity of 27.17% and a negative net margin of 81.75%.

When did Sol-Gel Technologies IPO?

Sol-Gel Technologies (SLGL) raised $60 million in an initial public offering on Thursday, February 1st 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. ​Jefferies and BMO Capital Markets​ served as the underwriters for the IPO and JMP Securities and Raymond James​ were co-managers.

Who are Sol-Gel Technologies' major shareholders?

Top institutional investors of Sol-Gel Technologies include Raymond James Financial Inc. (0.39%), Raymond James Financial Inc. (0.39%) and Concourse Financial Group Securities Inc..

How do I buy shares of Sol-Gel Technologies?

Shares of SLGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sol-Gel Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sol-Gel Technologies investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Pfizer (PFE), Alibaba Group (BABA), ADMA Biologics (ADMA) and Fortress Biotech (FBIO).

Company Calendar

• Last Earnings: 8/16/2024
• Today: 3/27/2025
• Next Earnings (Estimated): 5/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLGL
• CIK: 1684693
• Web: www.sol-gel.com
• Phone: (728) 931-3433
• Fax: 972-153-523044444
• Employees: 50
• Year Founded: 1997

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $6.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +834.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-27,240,000.00
• Net Margins: -81.75%
• Pretax Margin: -81.75%
• Return on Equity: -27.17%
• Return on Assets: -22.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.81
• Quick Ratio: 5.81

Sales & Book Value

• Annual Sales: $11.71 million
• Price / Sales: 1.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: 0.32

Miscellaneous

• Outstanding Shares: 27,858,000
• Free Float: 9,330,000
• Market Cap: $14.90 million
• Optionable: Optionable
• Beta: 1.29